Wenfeng Fang

9.8k citations
201 papers · 4.9k indexed · 2 hit papers · h-index 33

Wenfeng Fang

191 papers receiving 4.8k citations

Hit Papers

Camrelizumab (SHR-1210) alone or in combination with gemc...3262015202620182022100200300400500

Peers

Wenfeng Fang
Comparison fields: 5 of 122
  • Oncology 3.4k
  • Pulmonary and Respiratory Medicine 2.4k
  • Otorhinolaryngology 277
  • Cancer Research 890
  • Immunology 681
Replace Hidetoshi Hayashi with:
Hidetoshi Hayashi Japan
Yuanyuan Zhao China
Kenji Sugio Japan
Kazuko Sakai Japan
Miao‐Zhen Qiu China
Patrick M. Forde United States
Young Kwang Chae United States
Yan Sun China
Margarita Majem Spain
Andréa Varga France
Wenfeng Fang relative to Hidetoshi Hayashi Japan Hidetoshi Hayashi's profile →
Citations per field
00.5×4.1×
Hidetoshi Hayashi · 1×
Citations per year

Countries citing papers authored by Wenfeng Fang

Since Specialization
Citations

This map shows the geographic impact of Wenfeng Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenfeng Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenfeng Fang more than expected).

Fields of papers citing papers by Wenfeng Fang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenfeng Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenfeng Fang. The network helps show where Wenfeng Fang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Wenfeng Fang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wenfeng Fang Line = papers co-authored together Wenfeng Fang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20252
3 20250
4 20246
5 20241
6 202410
7 20242
8 202423
9 20231
10 20231
11 202334
12 202315
13 20231
14 20239
15 202232
16 202011
17 202015
18 2019139
19 201918
20 201410

About Wenfeng Fang

Wenfeng Fang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 201 papers that have together received 4.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (120 papers), Cancer Immunotherapy and Biomarkers (58 papers), Lung Cancer Research Studies (48 papers), Colorectal Cancer Treatments and Studies (33 papers), Cancer Genomics and Diagnostics (25 papers), Lung Cancer Diagnosis and Treatment (22 papers), HER2/EGFR in Cancer Research (15 papers) and Pancreatic and Hepatic Oncology Research (14 papers). The work is most often cited by research in Oncology (3.4k citations), Pulmonary and Respiratory Medicine (2.4k citations) and Otorhinolaryngology (277 citations). Wenfeng Fang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Shaodong Hong, Yan Huang, Yunpeng Yang, Hongyun Zhao, Yuxiang Ma, Li Zhang, Jianhua Zhan, Yaxiong Zhang, Li Zhang and Yuanyuan Zhao. Their work appears in journals such as JAMA, Journal of Clinical Investigation and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026